 |
|
The Automatic Implantable Cardioverter-DefibrillatorClinical Experience, Complications, and Follow-up in 25 Patients
Joseph Borbola, MD;
Pablo Denes, MD;
Marilyn D. Ezri, MD;
Robert G. Hauser, MD;
Cyrus Serry, MD;
Marshall D. Goldin, MD
Arch Intern Med. 1988;148(1):70-76.
Abstract
• Twenty-five patients with recurrent ventricular tachyarrhythmias underwent implantation of an automatic implantable cardioverter-defibrillator. The mean length of follow-up was 11.9±10.8 months. Before the implantation, the patients had survived one or more cardiac arrests (mean, 1.7; range, 1 to 4) and episodes of syncope (mean, 2.2; range, 2 to 3) and had received 6.0±1.0 antiarrhythmic drug trials. The in-hospital complications included death (two patients), reoperation (one patient), intraoperative myocardial infarction (one patient), sensing-failure (one patient), infection (five patients), and pocket seroma (two patients). The posthospital complications included device failure (four patients), device deactivation (one patient), and inappropriate discharge (two patients). The device discharged appropriately in seven patients due to sustained ventricular tachycardia. During electrophysiologic measurements, the energy requirement for successful cardioversion-defibrillation was related to the type of ventricular arrhythmia induced (monomorphic or pleomorphic ventricular tachycardia or fibrillation). Ventricular tachycardia acceleration occurred in ten patients (40%). No significant changes were found in the size of the electrograms or in the cardioversion threshold during early and late follow-up measurements. Life table analysis showed a 12-month survival rate of 86% and an arrhythmic death survival rate of 100%. We confirm the improved rate of survival in this high-risk group of patients, despite significant complications.
(Arch Intern Med 1988;142:70-76)
Author Affiliations
From the Department of Medicine, Section of Cardiology (Drs Borbola, Denes, Ezri, and Hauser), and the Department of Cardiovascular-Thoracic Surgery (Drs Serry and Goldin), Rush-Presbyterian—St Luke's Medical Center, Chicago.
Footnotes
Accepted for publication Sept 8, 1987.
Reprint requests to Department of Medicine, Section of Cardiology, Rush-Presbyterian—St Luke's Medical Center, 1750 W Harrison St, Chicago, IL 60612 (Dr Denes).
 CiteULike  Connotea  Delicious  Digg  Facebook  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Programming of Implantable Cardioverter-Defibrillators on the Basis of the Upper Limit of Vulnerability
Swerdlow et al.
Circulation 1997;95:1497-1504.
ABSTRACT
| FULL TEXT
Differential Effects of Lidocaine on Defibrillation Threshold With Monophasic Versus Biphasic Shock Waveforms
Ujhelyi et al.
Circulation 1995;92:1644-1650.
ABSTRACT
| FULL TEXT
Importance of complete system removal of infected cardioverter-defibrillators
Mull et al.
Ann. Thorac. Surg. 1995;60:704-706.
ABSTRACT
Surgical experience with defibrillator implantation using nonthoracotomy leads
Hammel et al.
Ann. Thorac. Surg. 1993;55:685-693.
ABSTRACT
Implantation of cardioverter defibrillators in the post-sternotomy patient
Damiano et al.
Ann. Thorac. Surg. 1992;53:978-983.
ABSTRACT
Silicone pouch for protection of automatic implantable cardioverter-defibrillator leads
Cilley et al.
Ann. Thorac. Surg. 1991;51:504-505.
ABSTRACT
|
